Literature DB >> 12667064

Integrin alpha4beta1-dependent adhesion to ADAM 28 (MDC-L) requires an extended surface of the disintegrin domain.

Lance C Bridges1, Krista R Hanson, Patricia H Tani, Timothy Mather, Ron D Bowditch.   

Abstract

ADAMs (a disintegrin and metalloprotease) are a family of proteins that possess functional adhesive and proteolytic domains. ADAM 28 (MDC-L) is expressed by human lymphocytes and contains a disintegrin-like domain that serves as a ligand for the leukocyte integrin, alpha4beta1. To elucidate which residues comprise the alpha4beta1 binding site in the ADAM 28 disintegrin domain, a charge-to-alanine mutagenesis strategy was utilized. Each alanine substitution mutant was evaluated and compared to the native sequence for its ability to support cell adhesion of the T-lymphoma cell line, Jurkat. This approach identified ADAM 28 residues Lys(437), Lys(442), Lys(455), Lys(459), Lys(460), Lys(469), and Glu(476) as being essential for alpha4beta1-dependent cell adhesion. The epitope for a function-blocking monoclonal antibody, Dis 1-1, was localized to the N-terminal end of the ADAM 28 disintegrin domain using these same charge-to-alanine mutants. Three distinct molecular models based upon the known structures of snake venom disintegrins suggested that residues contributing to alpha4beta1 recognition are aligned on one face of the domain. This study demonstrates that residues located outside of the disintegrin loop participate in integrin recognition of mammalian disintegrins.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12667064     DOI: 10.1021/bi026871y

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  8 in total

1.  Crystal structures of VAP1 reveal ADAMs' MDC domain architecture and its unique C-shaped scaffold.

Authors:  Soichi Takeda; Tomoko Igarashi; Hidezo Mori; Satohiko Araki
Journal:  EMBO J       Date:  2006-05-11       Impact factor: 11.598

2.  Multiple non-catalytic ADAMs are novel integrin α4 ligands.

Authors:  Lei Wang; Jason A Hoggard; Erica D Korleski; Gideon V Long; Brandy C Ree; Kenneth Hensley; Stephen R Bond; Tyra G Wolfsberg; JianMing Chen; Tonya N Zeczycki; Lance C Bridges
Journal:  Mol Cell Biochem       Date:  2017-09-14       Impact factor: 3.396

3.  ADAM disintegrin-like domain recognition by the lymphocyte integrins alpha4beta1 and alpha4beta7.

Authors:  Lance C Bridges; Dean Sheppard; Ron D Bowditch
Journal:  Biochem J       Date:  2005-04-01       Impact factor: 3.857

4.  Baseline and decline of serum ADAM28 during chemotherapy of advanced non-small cell lung cancer: a probable predictive and prognostic factor.

Authors:  Yan-ling Lv; Dong-mei Yuan; Qing-bo Wang; Ping Zhan; Liang Luo; Tang-feng Lv; Hong-bing Liu; Yu-feng Li; Jian Wen; Yong Song
Journal:  Med Oncol       Date:  2012-02-22       Impact factor: 3.064

5.  ADAM2 interactions with mouse eggs and cell lines expressing α4/α9 (ITGA4/ITGA9) integrins: implications for integrin-based adhesion and fertilization.

Authors:  Ulyana V Desiderio; Xiaoling Zhu; Janice P Evans
Journal:  PLoS One       Date:  2010-10-29       Impact factor: 3.240

6.  A disintegrin and metalloenzyme (ADAM) 17 activation is regulated by α5β1 integrin in kidney mesangial cells.

Authors:  Pal Gooz; Yujing Dang; Shigeki Higashiyama; Waleed O Twal; Courtney J Haycraft; Monika Gooz
Journal:  PLoS One       Date:  2012-03-08       Impact factor: 3.240

7.  ADAM8 as a drug target in pancreatic cancer.

Authors:  Uwe Schlomann; Garrit Koller; Catharina Conrad; Taheera Ferdous; Panagiota Golfi; Adolfo Molejon Garcia; Sabrina Höfling; Maddy Parsons; Patricia Costa; Robin Soper; Maud Bossard; Thorsten Hagemann; Rozita Roshani; Norbert Sewald; Randal R Ketchem; Marcia L Moss; Fred H Rasmussen; Miles A Miller; Douglas A Lauffenburger; David A Tuveson; Christopher Nimsky; Jörg W Bartsch
Journal:  Nat Commun       Date:  2015-01-28       Impact factor: 14.919

8.  miR-720 is a downstream target of an ADAM8-induced ERK signaling cascade that promotes the migratory and invasive phenotype of triple-negative breast cancer cells.

Authors:  Sonia G Das; Mathilde Romagnoli; Nora D Mineva; Sophie Barillé-Nion; Pascal Jézéquel; Mario Campone; Gail E Sonenshein
Journal:  Breast Cancer Res       Date:  2016-04-02       Impact factor: 6.466

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.